Entera Bio (NASDAQ:ENTX - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02, Zacks reports.
Entera Bio Price Performance
Entera Bio stock opened at $1.13 on Friday. The company has a market cap of $51.82 million, a price-to-earnings ratio of -4.35 and a beta of 1.83. The firm has a 50-day moving average of $1.37 and a 200-day moving average of $1.89. Entera Bio has a one year low of $0.98 and a one year high of $3.22.
Insider Buying and Selling
In related news, Director Geno J. Germano bought 20,000 shares of the business's stock in a transaction dated Monday, March 9th. The shares were purchased at an average price of $1.30 per share, with a total value of $26,000.00. Following the purchase, the director owned 40,000 shares of the company's stock, valued at approximately $52,000. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired a total of 69,000 shares of company stock valued at $92,530 over the last quarter. 10.38% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its position in shares of Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after purchasing an additional 43,536 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock worth $1,157,000 after buying an additional 29,629 shares during the period. Citadel Advisors LLC grew its holdings in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock worth $77,000 after purchasing an additional 28,322 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock valued at $210,000 after buying an additional 19,601 shares during the period. Institutional investors own 14.11% of the company's stock.
Analysts Set New Price Targets
A number of research firms have commented on ENTX. Wall Street Zen raised shares of Entera Bio to a "sell" rating in a research report on Saturday, December 27th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Entera Bio in a research note on Monday, February 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Entera Bio in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $10.00.
Read Our Latest Stock Report on ENTX
About Entera Bio
(
Get Free Report)
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
Featured Articles
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
